Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Fluoxetine 20 Mg Tabs Have 18% Share Of New Prescriptions

Executive Summary

Par's 20 mg tablet formulation of fluoxetine holds an 18% share of new prescriptions for the most common strength of Lilly's Prozac.

You may also be interested in...



Paxil Generics Grab 65% Of New Scripts; Apotex May Sue Over Par/GSK Deal

Generics of GlaxoSmithKline's antidepressant Paxil have captured 65% of the market for new paroxetine prescriptions, Apotex said

Paxil Generics Grab 65% Of New Scripts; Apotex May Sue Over Par/GSK Deal

Generics of GlaxoSmithKline's antidepressant Paxil have captured 65% of the market for new paroxetine prescriptions, Apotex said

The end of an era?

Barr launches generic fluoxetine 20 mg capsule Aug. 2 at $2.67 average wholesale price per capsule, a 10% discount to Lilly's Prozac. The launch follows entry of a final mandate in Prozac patent litigation in Indianapolis district court on July 27. Barr, Par and Geneva will have 180 days of Waxman/Hatch exclusivity on different fluoxetine formulations. Geneva's 10 mg capsule will have an AWP of $2.60; Par's fluoxetine formulations will launch with AWPs per pill of $2.60 (10 mg tablet), $2.67 (20 mg tablet) and $5.34 (40 mg capsule). Lilly's Prozac has a 24.3% share of the serotonin reuptake inhibitor market as of Aug. 3, according to data on the ArcLight "Rxeal Time" database. GSK's Paxil and Pfizer's Zoloft have a 27.2% and 30.0% share of this market, respectively

Related Content

UsernamePublicRestriction

Register

PS038452

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel